[go: up one dir, main page]

GT200600105A - Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos. - Google Patents

Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos.

Info

Publication number
GT200600105A
GT200600105A GT200600105A GT200600105A GT200600105A GT 200600105 A GT200600105 A GT 200600105A GT 200600105 A GT200600105 A GT 200600105A GT 200600105 A GT200600105 A GT 200600105A GT 200600105 A GT200600105 A GT 200600105A
Authority
GT
Guatemala
Prior art keywords
oxi
trifluorometil
phenyl
pirimidine
diamine
Prior art date
Application number
GT200600105A
Other languages
English (en)
Inventor
Julie A Dixon
Dhanapalan Nagarathnam
Lei Zhang
Chunguang Wang
Lin Yi
Yuanwei Chen
Jianging Chen
Brian R Bear
Michael Brands
Alexander Hillisch
Donald Bierer
Ming Wang
Weniang Fu
Martin F Hentemann
Ann-Marie Bullion
Manoj Patel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36624969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600105(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600105A publication Critical patent/GT200600105A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ESTA SOLICITUD ESTÁ RELACIONADA CON COMPUESTOS FARMACÉUTICOS HETEROCÍCLICOS DE MOLÉCULA PEQUEÑA Y, MÁS ESPECÍFICAMENTE, CON DERIVADOS DE PIRIMIDINA AMINOSUSTITUIDA, DE FÓRMULA GENERAL (I), CON ACTIVIDAD CITOTÓXICA DEL GRUPO INTEGRADO POR: 6-(2,6-DIMETILFENIL)-N-(4-((2-(TRIFLUOROMETIL)-PIRIDIN-4-IL)-OXI-FENIL)-PIRIMIDINA-2,4-DIAMINA), (6-(6-AMINOPIRIDIN-3-IL)-N-(4-((2-METILPIRIDIN-4-IL)-OXI)-FENIL)-PIRIMIDINA-2,4-DIAMINA), (N-(4-(2-(TRIFLUOROMETIL)-PIRIDIN-4-IL)-OXI)-FENIL)-4,5´-BIPIRIMIDINA-2,5-DIAMINA), (6-FENIL-N-(4-((2-TRIFLUOROMETIL)-PIRIMIDIN-4-IL)-OXI-FENIL)PIRIMIDINA-2,4-DIAMINA), (6-(6-AMINOPIRIDIN-3-IL)-N-(4-((2-(TRIFLUOROMETIL)-PIRIMIDIN-4-IL)-OXI)-FENIL)-PIRIMIDINA-2,4-DIAMINA), COMPOSICIONES FARMACÉUTICAS, PROCEDIMIENTOS DE PREPARACIÓN Y MÉTODO PARA TRATAR TRASTORNOS HIPERPROLIFERATIVOS. T2006
GT200600105A 2005-03-10 2006-03-09 Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos. GT200600105A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66056105P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
GT200600105A true GT200600105A (es) 2007-02-14

Family

ID=36624969

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600105A GT200600105A (es) 2005-03-10 2006-03-09 Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos.

Country Status (23)

Country Link
US (1) US20110098301A1 (es)
EP (1) EP1858882A1 (es)
JP (1) JP2008533042A (es)
KR (1) KR20080004488A (es)
CN (1) CN101151258A (es)
AR (1) AR053554A1 (es)
AU (1) AU2006223199A1 (es)
BR (1) BRPI0609022A2 (es)
CA (1) CA2601257A1 (es)
CR (1) CR9347A (es)
DO (1) DOP2006000061A (es)
EA (1) EA200701930A1 (es)
GT (1) GT200600105A (es)
IL (1) IL185498A0 (es)
MA (1) MA29377B1 (es)
MX (1) MX2007010102A (es)
NO (1) NO20074964L (es)
PE (1) PE20061067A1 (es)
TN (1) TNSN07322A1 (es)
TW (1) TW200724537A (es)
UY (1) UY29414A1 (es)
WO (1) WO2006099231A1 (es)
ZA (1) ZA200708591B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530386A (ja) * 2006-03-20 2009-08-27 バイエル・ヘルスケア・エルエルシー パクリタキセル組み合わせ物
EP2173722B1 (en) * 2007-07-26 2012-08-29 Novartis AG Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
AU2011310532B2 (en) 2010-10-01 2016-01-14 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
EA201390917A1 (ru) 2010-12-21 2013-12-30 Новартис Аг Дигетероарильные соединения в качестве ингибиторов vps34
PE20140502A1 (es) 2011-04-22 2014-05-02 Signal Pharm Llc Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas
KR20220143164A (ko) 2012-11-21 2022-10-24 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
CN103408573B (zh) * 2013-07-12 2015-12-23 上海工程技术大学 硼酸衍生物及其制备方法和应用
CA2922657C (en) 2013-08-30 2022-04-12 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
US9638690B2 (en) 2014-11-07 2017-05-02 The University Of British Columbia Compounds and compositions for use as alkylating agent sensors and methods of use thereof
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
MX2018001004A (es) 2015-07-24 2018-06-07 Celgene Corp Metodos de sintesis de clorhidrato de (1r,2r,5r)-5-amino-2-metilci clohexanol e intermedios utiles en este.
TWI609028B (zh) 2016-05-06 2017-12-21 財團法人工業技術研究院 共聚物與含其之樹脂組合物、封裝膜及封裝結構
BR112021002630A2 (pt) 2018-08-17 2021-05-11 Ptc Therapeutics, Inc. método para tratar câncer pancreático
CN111518078B (zh) * 2020-05-30 2021-02-26 南方医科大学 一种含氨基吡啶的嘧啶类化合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3089480B2 (ja) * 1990-09-20 2000-09-18 ソニー株式会社 フリットシール装置
US6943172B2 (en) * 2002-01-23 2005-09-13 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
US6924290B2 (en) * 2002-01-23 2005-08-02 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
WO2005035507A2 (en) * 2003-10-10 2005-04-21 Bayer Pharmaceuticals Corporation 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders

Also Published As

Publication number Publication date
US20110098301A1 (en) 2011-04-28
JP2008533042A (ja) 2008-08-21
TW200724537A (en) 2007-07-01
CN101151258A (zh) 2008-03-26
NO20074964L (no) 2007-12-06
DOP2006000061A (es) 2006-09-30
KR20080004488A (ko) 2008-01-09
CA2601257A1 (en) 2006-09-21
MX2007010102A (es) 2007-10-12
EP1858882A1 (en) 2007-11-28
UY29414A1 (es) 2006-10-02
PE20061067A1 (es) 2006-11-30
IL185498A0 (en) 2008-01-06
AU2006223199A1 (en) 2006-09-21
CR9347A (es) 2007-12-17
BRPI0609022A2 (pt) 2010-01-12
MA29377B1 (fr) 2008-04-01
TNSN07322A1 (en) 2008-12-31
EA200701930A1 (ru) 2008-02-28
AR053554A1 (es) 2007-05-09
ZA200708591B (en) 2009-01-28
WO2006099231A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
GT200600105A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos.
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
EA200901608A1 (ru) Производные хинаксолина в качестве ингибиторов тирозинкиназной активности киназ janus
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
ECSP109953A (es) Derivados de piridazinona
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
NZ598269A (en) Aryl sulphone derivatives as calcium channel blockers
PE20120120A1 (es) DERIVADOS DE 2H-PIRAZOLO[3,4-d]PIRIMIDINA-4,6(5H,7H)-DIONA, COMO INHIBIDORES DE PDE1
NO20076450L (no) Heterosykliske forbindelser som nikotinsyrereseptoragonister for behandling av dyslipidemi
MY155836A (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
NO20081349L (no) Pyrrolopyrimidinderivater som Syk-inhibitorer
NZ702571A (en) 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
ATE456565T1 (de) Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
ATE526328T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
WO2008059368A3 (en) Fused 2-amino pyrimidine compounds and their use for the treatment of cancer
PT1716152E (pt) Compostos heterocíclicos fundidos e sua utilização como antagonistas do receptor metabotrópico para o tratamento de distúrbios gastrointestinais
TW200628452A (en) Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents
PE20110584A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIMIDINA COMO INHIBIDORES DE MET, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU PROCEDIMIENTO DE PREPARACION
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
NO20091052L (no) Diaryleterderivater og anvendelser derav
DE602004014190D1 (de) 2-(1h-indolylsulfanyl)-benzylaminderivate als ssri